PT - JOURNAL ARTICLE AU - Carmine, Thomas Clemens TI - Variable Power Functional Dilution Adjustment of Spot Urine AID - 10.1101/2023.02.09.23285582 DP - 2024 Jan 01 TA - medRxiv PG - 2023.02.09.23285582 4099 - http://medrxiv.org/content/early/2024/05/29/2023.02.09.23285582.short 4100 - http://medrxiv.org/content/early/2024/05/29/2023.02.09.23285582.full AB - Spot-urinary biomarkers are essential for medical, epidemiological, and environmental research. However, they are affected by hydration-dependent diuresis, requiring precise dilution adjustments. Traditional methods, like conventional creatinine correction (CCRC), have limitations and introduce errors due to residual diuresis dependence. To address this, the WHO recommends a valid creatinine (CRN) range of 0.3-3 g/L. The present study introduces a novel numerical variable power functional CRN correction method (V-PFCRC). It was developed using 5553 spot urinary samples for total weight arsenic from a diverse population with generally low background exposure to inorganic arsenic from drinking water. The innovative V-PFCRC formula normalizes analytes (A) to 1 g/L CRN using uncorrected analyte levels and two analyte-specific coefficients, c and d: When applied to spot urinary arsenic, iodine, cesium, molybdenum, strontium, and zinc, the V-PFCRC method significantly reduced residual CRN bias. It performed better than uncorrected, conventionally (CCRC), and simple power functionally CRN-corrected (S-PFCRC) urine samples. V-PFCRC enhanced CRN-bias removal in entire datasets and within seven separately analyzed analyte levels (septiles), adequately compensating for non-linear, exposure-differentiated skews, including complex metabolic and excretory interactions between analytes and CRN. These advancements were supported by improved blood-urine correlations for iodine and arsenic in both sexes, suggesting a more accurate representation of supply and exposure than traditional urinary dilution corrections. The results underscore the superior performance of the V-PFCRC method in adjusting for hydration-dependent variability, surpassing traditional correction methods. The resource-efficient and versatile V-PFCRC method is easy to implement and holds immense potential for broader applications in various scientific and medical fields. This study advocates for the wider adoption of V-PFCRC to enhance the accuracy and reliability of urinary biomarkers, ensuring superior diagnostic and research outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethic committee of North west - and Central Switzerland (EKNZ), Hebelstrasse 53, 4056 Basel, Tel. 061 268 13 50, Fax 061 268 13 51 Email: eknz{at}bs.ch, gave ethical approval of this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsAsArsenicCCRCConventional Creatinine Correction (by calculating the ratio Analyte/CRN)CRNUrinary Creatinine Concentration (g/L)DMADimethylarsinic acidICP-MSInductively Coupled Plasma Mass SpectrometryIQRInterquartile RangeMMAMonomethylarsonic acidV-PFCRCVariable Power-Functional Creatinine Correction (using a variable exponent b)SAMES-Adenosyl-MethionineSDAESystemic Dilution Adjustment ErrorS-PFCRCSimple Power-functional Creatinine Correction (using a fixed exponent b)uAsCConventionally Creatinine-Corrected Urinary Arsenic (µg/g CRN)uAsNPower-functionally adjusted urinary arsenic, normalized to µg/1g CRNuAsUCUncorrected urinary arsenic (µg/L)UCUncorrected Urine Results (µg/L)UFRUrinary Flow Rate, Urine Excretion/Time (ml/min)